- Market cap
- $54.05B
Humana Inc. (HUM) is a Medical Specialities company listed on NYSE. In the last 30 days Quantisnow tracked 13 wire items for HUM, including 3 press releases and news items, 3 SEC filings and 3 insider trades. The most recent was published Nov 12, 2026.
HUM rankings
Financial highlights
Full financials- Revenue, TTM
- $154.19B
- Revenue growth
- +22.0%
- Net income, TTM
- $1.25B
- Net margin
- 0.8%
- Free cash flow, TTM
- $3.14B
- Cash
- $6.93B
For the twelve months ended Sep 30, 2026, from SEC filings. Not investment advice.
News · 26 weeks63-21%
2026-05-242026-11-15
Mix3690d
- Other15(42%)
- Insider6(17%)
- SEC Filings6(17%)
- Analyst4(11%)
- Earnings3(8%)
- Dividends2(6%)
Activity · 52 weeks17691 active days
Tap a day to see what happenedEarningsInsiderAnalystFilings and news
Our reporting on HUM
Latest news
25 items- INSIDERDirector Frederick Wayne A.I. sold $193,853 worth of Humana Common (440 units at $440.57), closing all direct ownership in the company (SEC Form 4)4 - HUMANA INC (0000049071) (Issuer)
- INSIDERPresident, Enterprise Growth Dintenfass David gifted 230 units of Humana Common, decreasing direct ownership by 0.91% to 25,177 units (SEC Form 4)4 - HUMANA INC (0000049071) (Issuer)
- INSIDERChief Legal Officer Ventura Joseph C sold $2,384,013 worth of Humana Common (5,495 units at $433.85) and gifted 437 units of Humana Common, decreasing direct ownership by 22% to 21,473 units (SEC Form 4)4 - HUMANA INC (0000049071) (Issuer)
- PRNew oncology model from Humana, Evolent and American Oncology Network eliminates prior authorization burdenProgram launched at American Oncology Network clinics across eight states.Humana Inc., in collaboration with Evolent Health, Inc. and American Oncology Network (AON), today announced the launch of a new cancer care model designed to improve the quality, timeliness and affordability of cancer care while reducing reliance on traditional prior authorization.The model has initially been rolled out across eight states to clinics within AON, one of the nation’s fastest-growing community oncology networks."We are committed to easing access to quality oncology care for our members and helping to reduce the administrative burden for providers," said Dr. Traci Granston, Humana Vice President of Clinic
- SECHumana Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - HUMANA INC (0000049071) (Filer)
- PRRaised Outlooks and a Cancer Approval Arrive in the Middle of Medicare Open EnrollmentNEW YORK, Nov. 9, 2026 /CNW/ -- Market Updates News Commentary - Health care stocks moved higher with the broader market on Monday morning. As of 9:58 a.m. ET, the State Street Health Care Select Sector SPDR ETF was up 0.88% at $186.42, while the S&P 500 was up 1.70% at 7,501.96. Medicare Open Enrollment is underway, and over the past week companies in pharmaceuticals, biotechnology, health insurance, medical devices and drug distribution have reported quarterly results or regulatory news. Active Companies from around the markets with current developments this week include: Johnson & Johnson (NYSE:JNJ), Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), Humana Inc. (NYSE:HUM), Edwards Lifesc
- PRHumana Commences Offers to Purchase for Cash Certain of its Outstanding Debt SecuritiesHumana Inc. (NYSE:HUM) ("Humana", "we", or "our") today announced that it has commenced cash tender offers (collectively, the "Offers") to purchase the outstanding notes described below, in each case upon the terms and subject to the conditions set forth in the Offer to Purchase dated November 9, 2026 (the "Offer to Purchase"). The Notes offered to be purchased in the Offers, in the order of acceptance priority, are the 2.150% Senior Notes due 2032; 3.125% Senior Notes due 2029; 3.700% Senior Notes due 2029; 4.875% Senior Notes due 2030; 1.350% Senior Notes due 2027; 3.950% Senior Notes due 2027; 5.375% Senior Notes due 2031; and 5.750% Senior Notes due 2028 (collectively, the "Notes") fo
- SECSEC Form 10-Q filed by Humana Inc.10-Q - HUMANA INC (0000049071) (Filer)
- SECHumana Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - HUMANA INC (0000049071) (Filer)
- PRHumana Reports Third Quarter 2026 Financial Results; Raises Full Year 2026 Adjusted EPS GuidanceReports 3Q26 earnings per share (EPS) of $1.33 on a GAAP basis, Adjusted loss per share of $0.70; reports year to date (YTD) 2026 EPS of $16.84 on a GAAP basis, $17.17 on an Adjusted basis 3Q26 Insurance segment GAAP benefit ratio of 93.7 percent, favorable to management's guidance of 'slightly above 94 percent' Raises FY 2026 Adjusted EPS guidance to now be 'at least $9.50', up from the previous expectation of 'at least $9.00'; while revising GAAP EPS guidance to 'at least $15.09', up from the previous estimate of 'at least $6.52' Continued strategic expansion of the company's CenterWell and Medicaid footprints YTD growth of 146,800 patients, or 30 percent, in CenterWell Senior
- PRHumana Board Declares Payment of Quarterly Dividend to StockholdersHumana Inc. (NYSE:HUM) announced today that its Board of Directors has declared a cash dividend to stockholders of $0.885 per share payable on January 29, 2027 to stockholders of record as of the close of business on December 24, 2026. About Humana Humana (NYSE:HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell healthcare services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at la
- PRVaxart Appoints Retired Vice Admiral Raquel C. Bono, M.D., to Board of DirectorsBoard-certified surgeon and former Director of the Defense Health Agency brings extensive leadership, public health and governance experience SOUTH SAN FRANCISCO, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Vaxart, Inc. (OTCQB:VXRT) (the "Company" or "Vaxart"), a clinical-stage biotechnology company developing a portfolio of oral recombinant vaccines based on its proprietary delivery platform, today announced the appointment of Raquel "Rocky" C. Bono, M.D., Vice Admiral, U.S. Navy (Ret.), to its Board of Directors. Dr. Bono was appointed pursuant to the cooperation agreement Vaxart entered into with a group of its stockholders in July 2026. She will serve as Chair of the Stockholder Engage
- PRThe Future of Healthcare: AI-Powered, Coordinated and Proactive CareAUSTIN, Texas, Oct. 19, 2026 (GLOBE NEWSWIRE) -- AINewsWire Editorial Coverage: American healthcare is moving from treating illness after it strikes to preventing it before it starts. U.S. health spending reached $5.3 trillion in 2024, and Medicare Advantage now covers 35.2 million people, or 55% of eligible beneficiaries. KFF projects Medicare Advantage payments of $574 billion in 2026, giving health plans a powerful reason to keep members healthy. That shift is opening the door for a new kind of player. ECGI Holdings Inc. (OTC:ECGI) (profile) has completed its acquisition of Avanta Group, a developing platform that spans a Medicare Advantage health plan, management services and AI-enable
- PRHumana Announces New Strategic Joint Venture with BlackRock to Manage CenterWell Senior Primary Care ClinicsThe new joint venture arrangement will replace CenterWell’s existing joint ventures with Welsh, Carson, Anderson & Stowe ("WCAS") through an acquisition of WCAS’s current equity stake by BlackRock.CenterWell Senior Primary Care will continue to manage and operate all clinics owned through the joint venture.Transaction is expected to provide Humana with enhanced balance sheet efficiency, additional growth capital, greater financial flexibility, and a reduced cost of capital.Anticipated additional capital commitment for the joint venture can fuel future growth and reinforce CenterWell’s position as the nation’s largest senior-focused primary care provider.Humana Inc. (NYSE:HUM) today announced
- SECSEC Form 8-K filed by Humana Inc.8-K - HUMANA INC (0000049071) (Filer)
- PRHumana Inc. to Release Third Quarter 2026 Results on November 6, 2026Humana Inc. (NYSE:HUM) will release its financial results for the third quarter 2026 (3Q26), as well as prepared management remarks (in PDF format), at 6:00 a.m. Eastern time on November 6, 2026. The company will host a live question-and-answer session at 8:00 a.m. Eastern time that morning to discuss its financial results for the quarter and earnings guidance for 2026. A webcast of the 3Q26 earnings call may be accessed via Humana’s Investor Relations page at https://humana.gcs-web.com/. If you anticipate asking a question during the question-and-answer session, please register in advance using this link, https://register-conf.media-server.com/register/BIe96a47a3d2724a5baa1fa1210aa58a1
- ANALYSTHumana upgraded by Raymond James with a new price targetRaymond James upgraded Humana from Mkt Perform to Outperform and set a new price target of $520.00
- PRAfter a Record-Setting Week, Wall Street Turns to Inflation Data and the First Big Earnings ReportsVANCOUVER, BC, Oct. 12, 2026 /PRNewswire/ -- American News Group News Commentary - The S&P 500 set an all-time high on Tuesday, October 6, and finished the week at 7,811.54 after a Friday gain of 0.6%, with the Dow Jones Industrial Average closing at 51,654.95 and the Nasdaq Composite at 27,366.17. All three finished the week higher, even as the 10-year Treasury yield recently reached its highest level since 2002 and closed Friday at 5.24%. The most active names of the week moved on company news: a satellite spectrum deal that hit wireless carriers, a Medicare ratings update, an airline outlook cut and a consumer staples guidance change. Next week brings September inflation data and the firs
- ANALYSTHumana upgraded by Robert W. Baird with a new price targetRobert W. Baird upgraded Humana from Neutral to Outperform and set a new price target of $596.00
- PRHumana Announces Improved CMS Star Ratings with 95 Percent of Medicare Advantage Members in 4-Star or Above Plans for 2027Significant performance improvement was achieved across all measure categories.The improvement in Star Ratings reflects Humana’s commitment to delivering a better customer experience and better health outcomes for members.Humana Inc. (NYSE:HUM), a leading consumer healthcare company focused on helping people achieve their best health, today announced improved Star Ratings for 2027, highlighted by 95% of its Medicare Advantage members being enrolled in plans rated 4.0 stars or above by the Centers for Medicare and Medicaid Services (CMS). Additionally, 42% of Humana Medicare Advantage members are enrolled in 4.5-star plans for 2027."We’re extremely proud of these Star Ratings. They’re a direc
- SECSEC Form 8-K filed by Humana Inc.8-K - HUMANA INC (0000049071) (Filer)
- ANALYSTHumana upgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald upgraded Humana from Neutral to Overweight and set a new price target of $460.00
- PRHumana Generates Nearly $20 Billion in Economic Impact Across Kentucky, New Report FindsIndependent analysis from the University of Louisville highlights Humana’s statewide contributions to jobs, healthcare and communities as Kentucky’s largest hometown company Humana Inc. (NYSE:HUM) and the University of Louisville today announced the publication of a new economic impact report examining Humana’s contributions across the state. The analysis, authored by University of Louisville applied economist Thomas E. Lambert, PhD, found that Humana’s operations generated nearly $20 billion in economic activity across Kentucky in 2025, supporting jobs, businesses and communities throughout the Commonwealth. The report, The Economic Impact of Humana and Humana Philanthropy on the Commo
- INSIDERSEC Form 4 filed by Director Hilzinger Kurt J4 - HUMANA INC (0000049071) (Issuer)
- PRHumana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027Humana Medicare Advantage Plans deliver care, coverage, and valuable benefits that support better health and affordability As Medicare’s Annual Election Period (AEP) begins Oct. 15, Humana is offering 2027 Medicare Advantage plans designed to deliver high-value coverage with affordable monthly premiums. Members will have continued access to the benefits they value most – including $0 cost-sharing on in-network primary care visits and labs plus dental, vision, and hearing coverage. Additional 2027 highlights include: Medicare Advantage plans in approximately 2,600 counties across 45 states and Washington, D.C., representing more than 80% of U.S. counties. Expanded Chronic Condition S
HUM FAQ
10 questionsWhat does Humana Inc. do?
Humana Inc., together with its subsidiaries, operates as a health and well-being company in the United States. It operates through Retail, Group and Specialty, and Healthcare Services segments. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits. In addition, the company provides commercial fully-insured...What is the latest news on HUM?
In the last 30 days Quantisnow tracked 13 wire items for HUM: 3 press releases and news items, 3 SEC filings, 3 insider trades and 1 leadership change. The most recent was published on November 12, 2026.What is HUM revenue?
Humana Inc. (HUM) reported $154.19B of revenue for the twelve months ended Sep 30, 2026. That is up 22.0% from the year before. Revenue for fiscal 2025 was $129.66B.Is HUM profitable?
Yes. Humana Inc. earned $1.25B in net income for the twelve months ended Sep 30, 2026, a net margin of 0.8%.How much cash and debt does HUM have?
Humana Inc. reported $6.93B in cash and cash equivalents and $12.50B of debt on its most recent balance sheet in SEC filings.Where does HUM stock trade?
Humana Inc. (HUM) is listed on NYSE.What sector and industry is HUM in?
Humana Inc. operates in the Health Care sector, Medical Specialities industry.What are analysts saying about HUM?
Across the last 8 analyst actions on Humana Inc., there were 7 upgrades and 1 downgrade. The most recent action was from Raymond James: Outperform with a $520.00 price target on 2026-10-12. Recent price targets range from $370.00 to $596.00.What companies are similar to HUM?
Notable peers in the same industry include ELV (Elevance Health Inc.), CVS (CVS Health Corporation), CI (The Cigna Group), UNH (UnitedHealth Group Incorporated), MOH (Molina Healthcare Inc). Compare HUM side-by-side with any of them on Quantisnow.How can I track HUM on Quantisnow?
Quantisnow aggregates Humana Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow HUM to receive live email and push alerts on every new disclosure.